Carrimycin for HLH patients with resistant infections
Part of Blood & lymphatic clinical trials.
This trial tests an oral antibiotic called carrimycin in people with HLH who have an infection that is not responding to standard antibiotics. The goal is to see if this new treatment can help clear the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HLH (a condition where the immune system overreacts)
- You have an active infection that has not improved after 72 hours of treatment with a carbapenem antibiotic
- You are over 18 years old
- You can take tablets by mouth
- You do not have severe liver problems, active hepatitis B or C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
Hear when a new Carbapenem Resistant Bacterial Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.